Table 5.

Gene mutation status in serous ovarian cancer according to the autophagy-related signature.

Characteristics		High-risk (n = 130)	Low-risk (n = 163)	p-value
BRCA1				0.0359
	mutation	9 (6.9%)	24 (14.7%)
	no mutation	121 (93.1%)	139 (85.3%)
BRCA2				0.0691
	mutation	9 (6.9%)	22 (13.5%)
	no mutation	121 (93.1%)	141 (86.5%)
BRCA1/2				0.0062
	mutation	18 (13.8%)	44 (27.0%)
	no mutation	112 (86.2%)	119 (73.0%)
CSMD3				0.5995
	mutation	10 (7.7%)	10 (6.1%)
	no mutation	120 (92.3%)	153 (93.9%)
FAT3				0.3241
	mutation	10 (7.7%)	8 (4.9%)
	no mutation	120 (92.3%)	155 (95.1%)
HMCN1				0.5481
	mutation	8 (6.2%)	13 (8.0%)
	no mutation	122 (93.8%)	150 (92.0%)
MUC16				0.1612
	mutation	7 (5.4%)	16 (9.8%)
	no mutation	123 (94.6%)	147 (90.2%)
RYR2				0.7849
	mutation	7 (5.4%)	10 (6.1%)
	no mutation	123 (94.6%)	153 (93.9%)
TP53				0.2953
	mutation	125 (96.2%)	160 (98.2%)
	no mutation	5 (3.8%)	3 (1.8%)
TTN				0.0884
	mutation	22 (16.9%)	41 (25.2%)
	no mutation	108 (83.1%)	122 (74.8%)
USH2A				0.3178
	mutation	12 (9.2%)	10 (6.1%)
	no mutation	118 (90.8%)	153(93.9%)